Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action RARITAN, N.J., Nov. 7, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) […]